PBS0.F Precision BioSciences, Inc.

Healthcare Biotechnology Frankfurt Exchange
8.14 EUR
Close of Nov 12, 2026
2.88 10.00
Market cap
EUR 311M
P/E
37.0x
P/B
6.62x
ROE
-151.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PBS0.F undervalued?

Graham number

The Graham number of Precision BioSciences, Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Precision BioSciences, Inc. fundamental analysis

No fundamental analysis for Precision BioSciences, Inc. yet.

Precision BioSciences, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Precision BioSciences, Inc.

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate inte…

Full company profile